Related Experiment Videos
Outpatient management of heart failure
1Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand.
Insights
Plasma B-type natriuretic peptides, including BNP and proBNP, can effectively guide heart failure treatment. BNP-guided therapy significantly reduced cardiovascular events in a clinical trial, offering an objective measure for optimizing patient care.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Management
Background:
- Heart failure diagnosis and treatment present challenges due to increasing prevalence and complexity.
- Plasma B-type natriuretic peptides (BNP) correlate with cardiac function and prognosis.
- An objective indicator is needed for heart failure diagnosis and treatment efficacy.
Purpose of the Study:
- To evaluate the role of plasma BNP levels in guiding outpatient heart failure treatment.
- To determine if BNP-guided therapy improves cardiovascular outcomes compared to clinical assessment alone.
Main Methods:
- A randomized trial involving 69 heart failure patients (LVEF < 40%, NYHA II-IV).
- Patients were assigned to treatment guided by plasma BNP levels or a clinical score.
- Primary endpoint was the total number of cardiovascular events.
Main Results:
- BNP-guided treatment significantly reduced cardiovascular events (19 vs. 54 events).
- Multivariate analysis showed a p < 0.001 for the reduction in events.
- Plasma BNP and aminoterminal proBNP demonstrated potential as objective therapeutic guides.
Conclusions:
- Plasma BNP levels can serve as an objective guide for optimizing heart failure treatment.
- BNP-guided therapy demonstrably improves cardiovascular outcomes in heart failure patients.
- Natriuretic peptides offer a promising tool for enhancing heart failure management strategies.
Abstract:
With the increasing prevalence of heart failure, the greater spectrum of proven therapies, the broader spectrum of cardiac dysfunction qualifying for treatment and the recognition that heart failure is difficult to diagnose, the need for an indicator of both the diagnosis and the efficacy of treatment in this condition is clear. Plasma concentrations of the B-type natriuretic peptides are related to cardiac function and cardiovascular prognosis. They parallel hemodynamic indicators of cardiac dysfunction and may therefore act as indicators of the adequacy of therapy. In the one published trial of outpatient treatment of heart failure guided by plasma BNP, 69 patients (LVEF < 40%, NYHA II-IV) were randomised to treatment according to plasma peptide levels or a clinical score. The primary end point of total cardiovascular events was reduced in BNP-guided patients (19 versus 54 events) with p < 0.001 in a multivariate analysis. The natriuretic peptides and particularly plasma BNP and aminoterminal proBNP promised to provide an objective guide for optimising treatment in heart failure.